AOD 9604, MOTS-c, and Tesamorelin Dosage: What the Research Shows

There is no single published dosage that combines AOD 9604, MOTS-c, and tesamorelin. Each compound has its own research range: AOD 9604 is usually discussed at 250–500 mcg per day, MOTS-c at roughly 5–10 mg per week, and tesamorelin at 2 mg once daily under its FDA-approved label. No controlled human trial has tested all three together, so any combined figure circulating online is extrapolation rather than evidence.

Dosage Comparison at a Glance

The table below summarizes the ranges most often cited in study summaries and product literature. These are not official recommendations, and only tesamorelin has an approved human dose.

Compound	What it is	Commonly cited research dose	Frequency	FDA status for human use
AOD 9604	Modified HGH fragment (amino acids 176–191)	250–500 mcg per day	Once or twice daily	Not approved
MOTS-c	Mitochondrial-derived peptide (16 amino acids)	5–10 mg per week	Split into 2–3 injections	Not approved
Tesamorelin	GHRH analog (Egrifta)	2 mg per day	Once daily, bedtime	Approved for HIV-associated lipodystrophy

Anyone searching for one clean aod-9604 mots-c tesamorelin dosage table should know that the three compounds were never studied as a group. Each number comes from separate research with different goals, subjects, and endpoints.

AOD 9604 Dosage Basics

AOD 9604 is a modified fragment of human growth hormone that was designed to influence fat metabolism without the growth-promoting effects of full HGH. Small human trials in the 2000s produced modest and inconsistent fat-loss results, and the compound was never approved for any human indication in the United States.

• Most frequently cited research range: 250–500 mcg per day subcutaneously.
• Some protocols split the dose into two injections; others use a single morning dose.
• Early clinical trials tested higher daily amounts, up to roughly 1 mg, with limited effect on body weight.
• The half-life is short, around 15–30 minutes, which is why daily or twice-daily use is discussed.

The aod 9604 dosage protocol on most vendor pages is a copy of the same handful of small studies, frequently reprinted without the original caveats attached.

MOTS-c Dosage: Weekly, Not Daily

MOTS-c is a 16-amino-acid mitochondrial-derived peptide studied mainly in cells and animals for effects on insulin sensitivity and metabolic stress. Human data is thin, and there is no approved dose for any indication.

• Frequently discussed range: 5–10 mg per week, often divided into two or three injections.
• Some protocols use 5 mg every other day; others prefer a single 10 mg weekly dose.
• Because the peptide clears quickly, weekly totals are usually split rather than given all at once.
• Reported side effects in anecdotal accounts are mostly limited to injection-site reactions.

Animal studies often used body-weight-adjusted doses that do not translate cleanly into human numbers. A milligram-for-milligram conversion from mouse data is not meaningful.

Tesamorelin Dosage: The FDA-Approved Reference Point

Tesamorelin is a growth hormone-releasing hormone analog approved by the FDA as Egrifta for reducing visceral fat in adults with HIV-associated lipodystrophy. It is the only one of the three compounds with an approved human dose and a defined safety profile.

• Approved dose: 2 mg subcutaneously once daily, typically at bedtime.
• The label recommends periodic monitoring of IGF-1 levels and blood sugar.
• Common reported effects include injection-site reactions, joint pain, and swelling.
• Tesamorelin raises endogenous growth hormone, so it works differently from AOD 9604, which does not act through the GH receptor.

Tesamorelin is not approved for general weight loss. Its indication is narrow, and its use outside that population is considered experimental.

AOD-9604, MOTS-c, and Tesamorelin Stack: What Is Actually Known

Nothing. No published human trial has combined these compounds, and no regulatory agency has reviewed them as a combination. If you are mapping out an aod-9604 mots-c tesamorelin stack, treat every number you find as unverified.

The aod 9604 vs tesamorelin comparison at least rests on real data for each compound separately: tesamorelin has randomized trials and a product label, while AOD 9604 has small, largely inconclusive studies. Using aod-9604 and mots-c together has never been evaluated in a controlled human trial at all.

Feature	AOD 9604	MOTS-c	Tesamorelin
Primary mechanism	HGH fragment; acts on fat cells	AMPK activation; metabolic regulation	Stimulates endogenous GH release
Human evidence level	Small trials, mixed results	Very limited	Randomized trials plus approved label
Half-life	Roughly 15–30 minutes	Short, minutes	Roughly 30 minutes
Typical monitoring discussed	Body composition	Glucose and insulin markers	IGF-1, blood sugar

A logical concern with stacking is overlap. Tesamorelin raises growth hormone and IGF-1, AOD 9604 was engineered to avoid that pathway, and MOTS-c works through cellular energy signaling. Layering them multiplies unknowns rather than evidence.

Safety, Legality, and Realistic Expectations

• AOD 9604 and MOTS-c are not FDA-approved for human use and are legally sold only as research chemicals.
• Tesamorelin is approved only for HIV-associated lipodystrophy, not for general fat loss.
• Unregulated peptides can be mislabeled, underdosed, or contaminated.
• Growth hormone-related compounds may affect blood sugar, IGF-1, and fluid retention.
• Anyone with a metabolic or endocrine condition should talk with a healthcare professional before using any peptide.

The Bottom Line

There is no validated combined dosage for AOD 9604, MOTS-c, and tesamorelin. The individual research ranges are roughly 250–500 mcg daily for AOD 9604, 5–10 mg weekly for MOTS-c, and 2 mg daily for tesamorelin — but only the last comes from an approved product label.

If a vendor presents a precise three-peptide protocol as established science, that is a red flag. Peptide research moves slowly, and the honest answer about combining these compounds is that the human data does not exist yet.

COMMON QUESTIONS

Frequently Asked Questions

What is the standard tesamorelin dosage?

The FDA-approved dose of tesamorelin is 2 mg injected subcutaneously once daily, usually at bedtime. That approval covers adults with HIV-associated lipodystrophy and visceral fat accumulation, not general weight loss. Anyone using it outside that indication is using it experimentally.

Can you stack AOD 9604 and MOTS-c safely?

There is no clinical data on using them together, and neither compound is FDA-approved for human use. Any safety claims for the combination are speculative. Talk to a healthcare professional before considering research peptides, especially if you have a metabolic condition.

Is AOD 9604 a replacement for tesamorelin?

No. They work through different pathways: tesamorelin stimulates your own growth hormone release and has an approved label, while AOD 9604 is a modified HGH fragment that does not act through the growth hormone receptor. AOD 9604 failed to show consistent fat-loss results in small human trials and is not approved for any use in the United States.